Semaglutide Pill Rybelsus Offers Heart Benefits Comparable to Injectables
Novo Nordisk's Rybelsus, an oral semaglutide, reduces the risk of major cardiovascular events by 14% in type 2 diabetes patients, matching the benefits of injectable versions.
Published on April 3, 2025
Recent studies presented at the American College of Cardiology meeting indicate that Novo Nordisk’s oral semaglutide, Rybelsus, provides cardiovascular benefits similar to those of injectable GLP-1 drugs. A large Phase III trial demonstrated a 14% reduction in major adverse cardiovascular events—such as heart-related death, heart attack, and stroke—in patients with type 2 diabetes.
Additional reports, including one from Reuters on April 2, 2025, and corroborative summaries from BioSpace and Benzinga, underscore the promise of Rybelsus as a non-injectable treatment option. These findings support ongoing regulatory efforts for a label expansion in both the U.S. and the EU, marking a significant advancement in diabetes and heart treatment strategies.